The whole Oscar ‘smack’ melodrama was yet another Pfizer scam!

Posted on April 1, 2022 by State of the Nation

Who Sponsored The Oscars Explains It All!

Posted on March 30, 2022 by Constitutional Nobody

We are being played by the elites…

How many times does the public like being played by the elites?

The attention-grabbing storyline from the 2022 Academy Awards was Will Smith smacking Chris Rock in the face due to an insult against his wife over her hair loss condition (alopecia).

Personally, I think the shenanigans were a staged event.

Actors acting, right?

What do you think after watching the footage?

Whether Smith’s smack was real or fake, the sponsors of the Oscars smacked the daylights out of the global population.

Check out who sponsored Hollywood’s big night:

Could the ‘incident’ involving alopecia be free publicity for Pfizer’s soon-to-be-approved medication for the hair loss condition?

Fierce Pharma wrote:

Oscar-winning actor Will Smith slapping comedian Chris Rock made the biggest headlines out of the Oscars Sunday night. But the sponsorship from Pfizer and COVID shot partner BioNTech was for the pharma marketing world a bigger moment.

“Pfizer and BioNTech are proud to support the Oscars, and we are heartened to see the film industry gather in person and alongside fans to celebrate the talent and artistry produced during the past year,” a Pfizer spokesperson told Fierce Pharma Marketing.

As noted in Pfizer’s documents, Alopecia Areata is listed as one of the potential side effects of the COVID-19 shot.

The timing couldn’t have worked better for Pfizer since clinical trials for their Alopecia Areata treatment were updated February 24, 2022.

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Pfizer made this announcement last year:

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2 Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 percent scalp hair loss after six months of treatment versus placebo.

“We are pleased by these positive results for ritlecitinib in patients with alopecia areata, a devastating and complex autoimmune disease for which there are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 percent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score. A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 percent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo. This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups. The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles). There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

While the public continues arguing about Will Smith’s slap, Pfizer heads to the bank for another humungous payout.

Will the masses ever get tired of being played by the global elites, Hollywood, and Big Pharma?

Sources: WLT, Pfizer, Fierce Pharma, clinical trials

Click this link for the original source of this article.
Author: joe

___
https://ussanews.com/2022/03/30/who-sponsored-the-oscars-explains-it-all/

This entry was posted in Uncategorized. Bookmark the permalink.